Nimvec™ AM510
Type 1 Diabetes
Pre-clinicalActive
Key Facts
About Amarna Therapeutics
Amarna Therapeutics is a pioneering Dutch biotech company focused on next-generation gene therapy. Its core asset is a proprietary, non-immunogenic viral vector platform (Nimvec™) engineered to overcome key limitations of existing gene delivery systems, such as pre-existing immunity and immunogenicity. The company is leveraging this platform to build a pipeline of potentially curative therapies, with its lead program, AM510 for Type 1 Diabetes, advancing toward clinical trials through a strategic partnership. Operating as a private, pre-clinical, and pre-revenue entity, Amarna aims to unlock the full potential of gene therapy for a broad range of conditions.
View full company profileOther Type 1 Diabetes Drugs
| Drug | Company | Phase |
|---|---|---|
| eRapa | Biodexa Pharmaceuticals | Preclinical |
| ImmCelz™ | Creative Medical Technology Holdings | Clinical Trial |
| Adimune (ADi-001/002) | Aditxt | Preclinical / Early Clinical |
| MSC‑Diabetes | Advancells | Phase 1 |
| BioChaperone® Lispro (THDB0206) | Adocia | Phase 3 |
| AdoShell® Islet Cell Therapy | Adocia | Preclinical |
| Pediatric Indications (<2 years) | Tandem Diabetes | Research |
| Icovamenib (BMF-219) | Biomea Fusion | Phase 2 |
| Undisclosed Novel Strategy | CG Scientific | Pre-clinical |
| Sotagliflozin | Lexicon Pharmaceuticals | Phase 3 |
| Stem Cell-Derived Beta Cells | BioTalentum | Pre-clinical |
| NICHE | Continuity Biosciences | Pre-clinical |